Skip to main content

Table 1 Patient disposition (safety population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

Disposition, n (%)

Diabetes

n = 245

No diabetes

n = 1802

Patients completing the studies

230 (93.9)

1726 (95.8)

Most common reasons for premature withdrawal from the study

 AEs

5 (2.0)

16 (0.9)

 Patient’s decision

6 (2.4)

29 (1.4)

Patients completing study drug

200 (81.6)

1528 (84.8)

Most common reasons for discontinuing study drug

 AEs

8 (3.3)

32 (1.8)

 Patient’s decision

7 (2.8)

36 (2.0)

 Lack of efficacy

5 (2.0)

11 (0.6)

  1. AE adverse event